Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Theradex"
Count: 33
Selected: 0
NCT00111904Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
NCT00003160Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
NCT00069966Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
NCT00053105Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00024375DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer
NCT00039169BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
NCT00039156BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00025688Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
NCT00024414DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
NCT00024401DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
NCT00024388Chemotherapy in Treating Patients With Metastatic Kidney Cancer
NCT00024362BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery
NCT00014547BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment
NCT00003327Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
NCT00003326Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
NCT02309892A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
NCT04203641L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT05732103A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
NCT02879669A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
NCT02272855A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
NCT02372240A Study of VLX1570 and Dexamethasone in Myeloma Patients
NCT02222363Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
NCT04888312Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
NCT02529930An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
NCT03008187SEL24/MEN1703 in Patients With Acute Myeloid Leukemia
NCT01986426LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
NCT01035502A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
NCT01308762A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
NCT05280314Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
NCT04061421Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
NCT05077709IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
NCT01258816The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
NCT03402841Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients